When was Actelion founded?
Who founded Actelion?
How was Actelion originally financed?
To what extent are venture capitalists involved with Actelion today?
Where is Actelion listed?
When was Actelion listed?
What are the details of Actelion’s IPO?
What are the details of Actelion’s secondary offering?
Has there been a split in the stock since the IPO?
What is Actelion’s trading symbol?
Which indices is Actelion part of?
What is the split between institutional and retail shareholders of Actelion?
When was Actelion founded?
Actelion Pharmaceuticals Ltd was founded on 17 December 1997.
Who founded Actelion?
In legal terms, the founders were:
Jean-Paul Clozel (CEO)
Walter Fischli (Head of Drug Discovery, Biology)
Thomas Widmann (former CEO)
Additional members of the founding team were:
Martine Clozel (Head of Drug Discovery, Pharmacology & Preclinical development)
Andre J. Mueller (former CFO, now member of the Board of Actelion)
How was Actelion originally financed?
There were two venture capital (VC) financing rounds. The first VC round raised CHF 18 million in April 1998; the second round raised CHF 38 million in equity and CHF 10 million in credit facilities in March 1999.
To what extent are venture capitalists involved with Actelion today?
There are effectively no venture capitalists currently involved with Actelion.
Where is Actelion listed?
Actelion is listed as part of the Swiss Market Index (SMI®) of the Swiss Stock Exchange (SIX).
When was Actelion listed?
The registered shares of Actelion were first listed at the Swiss Stock Exchange (SIX) New Market on 6 April 2000. In September 2002, the company moved to the main market segment of the SIX. On 22 September 2008, Actelion traded for the first time as part of the Swiss Market Index (SMI®), the Swiss blue-chip index.
What are the details of Actelion’s IPO?
The registered shares of Actelion Ltd were first listed on the Swiss Stock Exchange (SIX) New Market on 6 April 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company's Initial Public Offering (IPO), at a price of CHF 260 per share (a price of 13 CHF after two stock splits which occurred in 2001 and 2007). Actelion's IPO was effected through an international banking syndicate led by Credit Suisse First Boston, and constituted one of the largest ever to take place for a biopharmaceutical company, raising CHF 246.6 million.
What are the details of Actelion’s secondary offering?
A secondary offering took place in April 2001 to allow a controlled share disposal. Actelion employees sold shares to cover tax liabilities as a result of the successful IPO. (Other shareholders also participated in the controlled disposal of shares into the marketplace). There were no net proceeds to the company.
Has there been a split in the stock since the IPO?
Actelion has announced a split of its shares on two occasions, the first on 20 June 2001 when Actelion announced a four-to-one split of its shares, and the second on 6 June 2007 when Actelion announced a five-to-one split of its shares. For example a share purchased at IPO for 260 CHF would be equivalent to 20 shares at a cost of 13 CHF today.
What is Actelion’s trading symbol?
ATLN.s (Reuters)
ATLN (Bloomberg)
Which indices is Actelion part of?
AS of September 2008 Actelion Ltd is part of the following indices: SMI, SPI, SLI, SMIM, SPIMLC, SPI20, SPISMC, SXXP, SXDP, SBC100, SNSPIX, SMHCAX, SLDI, SXI LIFE SCIENCES and SXI Bio+Medtech.
What is the split between institutional and retail shareholders of Actelion?
Based on an analysis of registered shareholders Actelion assumes that the majority of its stock is held by institutional shareholders.
